Autoimmune Encephalitis Alliance and Option Care co-sponsoring Mayo Clinic Trial on IVIg January 16, 2017

The Autoimmune Encephalitis Alliance and Option Care Enterprises, Inc. are co-sponsoring a clinical trial at Mayo Clinic to evaluate intravenous immunoglobulin (IVIG) treatment in patients with autoimmune epilepsy who fail to benefit from standard epilepsy medications. This study, the first of its kind, builds on Mayo Clinic research advances identifying new approaches to the diagnosis and treatment […]

New treatment for anti-NMDAR autoimmune encephalitis reports Charité – Universitätsmedizin Berlin February 2, 2017

One of the one of the largest university hospitals in Europe, Charite’, recorded significant progress in treating anti-NMDAR, including in patients who did not previously respond to treatment. Anti-NMDA receptor encephalitis is an inflammatory disease that affects the central nervous system. It is a rare autoimmune disease that results in the body producing antibodies against […]

Lancet Neurology publishes paper on brain imaging and diagnosis of autoimmune encephalitis March 9, 2017

It is often difficult to clinically diagnosis autoimmune encephalitis because patients’ symptoms can be so widely varied. In the Sept. 2016, issue of The Lancet Neurology, Francesc Graus and colleagues proposed an initial diagnostic work-up relying on conventional neurological evaluation and standard diagnostic tests such as MRI, CSF sampling, and EEG. This approach would enable clinicians to make […]

Bortezomib Treatment for Anti-NMDAR Autoimmune Encephalitis March 28, 2017

The Journal of the American Medical Association Nuerology reports the following by authors Volker Behrendt, MD1; Christos Krogias, MD1; Anke Reinacher-Schick, MD2; Ralf Gold, MD1; and Ingo Kleiter, MD1: Anti-NMDAR  autoimmune encephalitis, associated with ovarian teratoma, predominantly affects young females.1 Because antibodies against subunits of the NMDAR contribute to the pathogenesis, methods targeting humoral immunity are therapeutically efficacious.2 However, some patients have an unsatisfactory outcome after high-dose corticosteroids, apheresis […]

From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time April 18, 2017

Science Direct has published an article by authors van Sonderen, M.W.J. Schreurs , P.W. Wirtz , P.A.E. Sillevis Smitt, and M.J. Titulaer that a wide variety of clinical syndromes has been associated with antibodies to voltage-gated potassium channels (VGKCs). Six years ago, it was discovered that patients do not truly have antibodies to potassium channels, but […]

FDA approves drug for relapsing forms of multiple sclerosis – possible implications for autoimmune encephalitis? April 26, 2017

Medpage Today reports that the FDA has approved the biologic drug ocrelizumab (Ocrevus) for treatment of relapsing forms of multiple sclerosis. Ocrelizumab is an anti-CD20 monoclonal antibody targeting B cells which is the same mechanism of action as rituximab (Rituxan), which some earlier studies found to be effective against both relapsing-remitting and progressive MS. Off-label use of rituximab […]

Treatment of autoimmune encephalitis with immune based therapies June 6, 2017

The Journal of Neurology, Neuroscience, and Psychiatry reports on autoimmune encephalitis patients treated with immune based therapy including rituximab.  Authors Dowland F, Swayne A, Bhuta S, et. al. discuss three cases and conclude, “The field of neuro-immunology has seen a plethora of newly discovered autoantibodies, yet there remain a significant number of patients, with features suggestive […]

Targeted Therapy Holds Future Promise July 9, 2017

In many areas of medicine, treatments are increasingly becoming targeted in a way that benefits patients. This is happening in fields ranging from oncology to neurological disease. In this month’s Neurology Now, treatment for autoimmune encephalitis is being cited as one area where “precision medicine” holds promise for better and targeted treatments according to antibody […]

Autoimmune encephalitis in children – June 2017 review July 12, 2017

Researchers in three countries have come together to publish a review article in Current Opinion in Neurology, June 2017. Issues addressed in this comprehensive publication include: challenges in diagnosis, antibody detection methods, treatment decisions, seronegative cases and the challenges in monitoring patients over time. Points of emphasis include the following: Many autoimmune encephalopathies are central […]

Steady progress: Review article on autoimmune encephalitis and how field is evolving July 31, 2017

As difficult as diagnosis and treatment are for autoimmune encephalitis, fortunately for the community of patients, families, and caregivers, rapid progress has been made within only a decade. A group of physicians in Oxford, England has published a review for the journal Neuropharmacology that summarizes the various types of AE, including a classification of syndromes, […]